Clinical Research Centre
Hospital Tuanku Ja'afar
Seremban, Negeri Sembilan
WhoWe Are
Established in September 2006 as part of the Institute for Clinical Research (ICR) network under Malaysia's Ministry of Health, the Clinical Research Centre Hospital Tuanku Ja’afar Seremban (CRC HTJS) aims to become a leading regional clinical research institution by improving patient outcomes through ethical and high-quality research, and supports this mission with a comprehensive database of clinicians, technical and administrative support, assistance with NMRR protocol registration and grant applications, participation in clinical trials, and capacity-building through ongoing training and workshops.
OurTeam
InvestigatorsHighlight
Head of CRC, Head and Consultant Nephrology Department, Hospital Tuanku Ja’afar Seremban
Email: lilymushahar@gmail.com
MD, MMed
Areas of interest: Advancing peritoneal dialysis techniques, improving training and education for healthcare providers, and contributing to nephrology research and discourse.
Awards and achievements:
- Recipient of the Negeri Sembilan State Honorary Award (Darjah Setia Bakti (2024), Darjah Pekerti Terpilih (2015), Ahli Setia Negeri Sembilan (2012))
- Excellent Service Award, Ministry of Health Malaysia in 2001, 2008, and 2015
Dr. Lily Mushahar, MD, MMED is the Head and Consultant Nephrologist of the Department of Nephrology, Hospital Tuanku Ja’afar Seremban, Negeri Sembilan. She is also the Head of Clinical Research Centre Negeri Sembilan. Dr. Lily received her medical undergraduate end post-graduate degree at University Science Malaysia and received Nephrology fellowship training at the University of North Staffordshire Hospital, Stoke-on-Trent, United Kingdom. Dr. Lily focuses on peritoneal dialysis, developing training programs for Malaysian healthcare professionals, publishing in leading journals like Peritoneal Dialysis International and Kidney International, presenting at conferences, and reviewing for journals such as Peritoneal Dialysis International and Nephrology.
Research Highlights
- Treatment of CVD with Low Dose Rivaroxaban in Advanced CKD (TRACK)
- Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination with Dapagliflozin on CKD Progression in Participants with CKD and Highblood pressure (BaxDuo)
- Phase 3 Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN)(ICAN)
- Efficacy ,Safety and Tolerability of Zibotentan/Dapaglifozin Compared to Dapaglifozin on patient with CKD and High proteinuria (ZENITH)
- ldosterone Blockade for Health Improvement Evaluation in End Stage Renal Disease (ACHIEVE) Study
- The Study of Heart and Kidney Protection with Empagliflozin (EMPA-KIDNEY)
- PD Related Outcome in South East Asean (PROMiSE) Study
Recent Publications
Project Highlights
Efficacy of Color-Coded Visual Chart on Health Literacy and Patient Empowerment among Diabetic Populations (iHELP)
This is a prospective cohort study, where subjects were randomized into intervention and control groups. Intervention groups were given a diary containing iHELP chart that were plotted during appointments and were allowed back home for them to see the severity of illnesses they are at. While the control group are managed as the standard of care without the diary. Patients were followed up every 3-months for 5 years. This study aims to improve health literacy by using visual tool as a teaching aid that improve one’s knowledge measure by blood sugar and blood pressure control throughout the 5 years study period.
|
NMRR-18-1349-39723 |
Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease (ACHIEVE) |
| NMRR-21-497-58969 | Efficacy of color coded visual chart on Health Literacy and Patient Empowerment among diabetic populations (iHELP) |
| NMRR-22-00914-7ZJ | PD Practices and Outcomes of Multiple Countries in South East Asia (PROMiSE) |
| NMRR-24-01230-LGS | A Cross-Sectional Study Of Interfacility Transfers From Government Health Clinics To Tertiary Centre By Primary Health Care Ambulance Service In Seremban District |
| NMRR-15-2181-28116 | A Phase 3, Randomized, Double-Blind Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Moderately to Severely Active Rheumatoid Arthritis Who are on a Stable Background of Methotrexate (MTX) and Who Have an Inadequate Response to MTX (MTX-IR) |
| NMRR-17-1007-35866 | A Phase 3, Randomized, Double-Blind, Study Comparing ABT-494 to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a history of Inadequate Response to at least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) |
| NMRR-17-1530-34050 | A 26 Week, Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase 3 Trial with a 26 Week Safety Extension Period Evaluating the Safety and Efficacy of Dapagliflozin 5 and 10 mg, and Saxagliptin 2.5 and 5 mg in Pediatric Patients with Type 2 Diabetes Mellitus who are between 10 and below 18 years of age. |
| NMRR-18-3266-45336 | A Phase 3 Study of Etelcalcetide in Pediatric Subjects With SHPT and CKD on Hemodialysis |
| NMRR-18-2961-44888 | A Phase 3, Randomized, Double-Blind, Study Comparing Risankizumab to Placebo in Subjects with Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy |
| NMRR-19-1258-47901 | Semaglutide Cardiovascular Outcomes Trial In Patients With Type 2 Diabetes |
| NMRR-20-1140-53693 | Treatment of Cardiovascular Disease with Low Dose Rivaroxaban in Advanced Chronic Kidney Disease |
| NMRR-20-1829-56145 | A Double-Blind, Randomized, Parallel-Group Study with Quetiapine Extended Release as Comparator to Evaluate the Efficacy and Safety of Seltorexant 20 mg as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy |
| NMRR-21-23-57953 | A Double-Blind, Placebo-Controlled, Randomized Dose-Ranging Trial To Investigate Efficacy And Safety Of Intravenous MIJ821 Infusion In Addition To Comprehensive Standard Of Care On The Rapid Reduction Of Symptoms Of Major Depressive Disorder In Subjects Who Have Suicidal Ideation With Intent |
| NMRR-21-760-59664 | Effects Of Ziltivekimab Versus Placebo On Cardiovascular Outcomes In Participants With Established Atherosclerotic Cardiovascular Disease, Chronic Kidney Disease And Systemic Inflammation |
| NMRR-21-1256-60314 | A Phase 4, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Bio-naive Participants with Active Psoriatic Arthritis Axial Disease |
| NMRR-21-1271-60302 | A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Phase 3 Study To Investigate The Efficacy And Safety Of Finerenone, In Addition To Standard Of Care, On The Progression Of Kidney Disease In Patients With Non-Diabetic Chronic Kidney Disease. |
| NMRR-22-00990-UVQ | A Phase IIb/III Randomized, Double‐blind, Placebo‐controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non‐cirrhotic Non‐alcoholic Steatohepatitis with Fibrosis |
| NMRR-22-00939-JMZ | A phase III randomized, double-blind, placebo-controlled, parallel group trial to examine the efficacy and safety of BI 425809 once daily over 26 week treatment period in patients with schizophrenia |
| NMRR-22-00606-LIM | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects with Immunoglobulin A Nephropathy Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy |
| NMRR-22-01779-FM3 | Efficacy and safety of cagrilintide s.c. 2.4 mg in combination with semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) once-weekly in participants with overweight or obesity and type 2 diabetes |
| NMRR-22-02592-LFW | A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Subcutaneously Administered Guselkumab in Improving the Signs and Symptoms and Inhibiting Radiographic Progression in Participants With Active Psoriatic Arthritis |
| NMRR-22-02508-FAQ | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele |
| NMRR-22-02861-EQN | TESTING ON therapeutic Evaluation of STeroids in IgA Nephropathy Global |
| NMRR-23-00525-RKY | A Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Effect of Inclisiran on Preventing Major Adverse Cardiovascular Events in High-risk Primary Prevention Patients |
| NMRR-23-01234-LQE | A Phase 3 Study to Evaluate the Efficacy and Safety of Guselkumab Subcutaneous Induction Therapy in Participants with Moderately to Severely Active Ulcerative Colitis |
| NMRR-23-00431-W0Q | An Open Label, Single Arm, Extension Trial to Examine Long-term Safety of BI 425809 Once Daily in Patients With Schizophrenia Who Have Completed Previous BI 425809 Phase III Trials |
| NMRR-23-01871-OBV | A Randomized, Double-Blind, Parallel Group, Multicenter 12 Week Study to Assess the Efficacy and Safety of Budesonide and Formoterol Fumarate Metered Dose Inhaler Relative to Budesonide Metered Dose Inhaler in Participants With Inadequately Controlled Asthma |
| NMRR-23-02850-UTZ | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Tozorakimab in Participants With Symptomatic Chronic Obstructive Pulmonary Disease (COPD) With a History of COPD Exacerbations |
| NMRR-23-02339-9YB | A Multi-center, Randomized, Double-blind, Active-controlled, Therapeutic Confirmatory, Phase III Study to Compare and Evaluate the Efficacy and Safety of Epaminurad With Febuxostat in Gout Patients |
| NMRR-23-03240-K1D | An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with Transfusion-dependent beta thalasemia |
| NMRR-23-00338-JHM | A randomized, double-blind, placebo-controlled multicenter phase 3 study to evaluate efficacy, safety and tolerability of ianalumab on top of standard-of-care therapy in patients with systemic lupus erythematosus |
| NMRR-24-00101-57J | A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety, and Tolerability of Zibotentan / Dapagliflozin Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Protenuria (D4325C00010) |
| NMRR-24-00447-ZUI | A Phase III, Randomised, Multicentre, Double-blind, Active- Controlled Study to Assess the Efficacy, Safety, and Tolerability of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone in Chronic Kidney Disease (CKD) Progression in Participants with CKD and High Blood Pressure |
| NMRR-24-01049-OBB | A Phase 3, Randomised, Double - Blind, Placebo - Controlled Study to Evaluate the Efficacy and Safety of Ravulizumab in Adult Participants with Immunogloblin A Nephropathy (IgAN) |
| NMRR-24-00684-4OE | A Randomized, Double-blind, Parallel Group, Multi-centre, Phase III Study to Assess the Efficacy of Budesonide, Glycopyrronium, and Formoterol Fumarate Metered Dose Inhaler Relative to GLycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease |
| NMRR-24-01820-XX9 | A Multi-Centre, Randomised, Parallel Group, Double Blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Palcebo in Male and Famale Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis |
| NMRR-24-02323-VXO | Phase 3, Randomized, Modified Double-blind, Active-controlled, Parallel-group Study to Investigate the Safety and Immunogenecity of Catch up Vaccination Regimens of a 21-Valent Pneumococcal Conjugate Vaccine in Healthy Infants, Toddlers, Children and Adolescents |
List of Publications associated with CRC HTJS
- Knowledge, Attitude and Practices of Dengue Patient Admitted to Hospital Tuanku Jaafar, Seremban, Malaysia
- Anis Ahmed Khan, Noor Lita, Lim Wu Tzin, Liew Siet Wen, Lio Rui Yin, Lee Ying Hwei, Lee Zoe Jean
Services at CRC Hospital Tuanku Ja'far Seremban
CRC HTJS conducts Clinical Research & Trials
- Promote and support industry sponsored and investigator-initiated trials/research (IIR & ISR)
- Provide Administrative and Facility Support
- Local Research Registration and Monitoring
CRC Hospital Tuanku Ja'afar Seremban
Main Phone: +606-762 3333
Email: seremban@crc.moh.gov.my
